Bicycle Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on the stock and has a $15.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ami Fadia has given his Buy rating due to a combination of factors tied to encouraging early clinical and preclinical data for Bicycle Therapeutics’ lead asset, nuzefatide pevedotin. In metastatic urothelial carcinoma, the drug’s combination with nivolumab produced a 100% response rate in EphA2‑positive, MMAE‑naïve patients and a 40% overall response rate in the EphA2‑positive subgroup, which compares favorably to prior, largely unsuccessful efforts to drug EphA2.
Beyond urothelial cancer, initial pancreatic cancer data showed rapid tumor localization with clearance mainly via the kidneys in most patients, and preclinical models indicated broad sensitivity, suggesting meaningful expansion potential. Similar supportive preclinical findings in head and neck squamous cell carcinoma further strengthen the multi‑tumor opportunity, and investors are also anticipating more detailed Phase 2 results for zelenectide pevedotin in first‑line mUC, which together underpin Fadia’s constructive view on BCYC’s valuation and growth prospects.